Variability of EGFR exon 20 insertions in 24 468 Chinese lung cancer patients and their divergent responses to EGFR inhibitors

EGFR exon 20 insertions (EGFR e20ins) account for up to 10% of EGFR mutations in lung cancer; however, tumors with EGFR e20ins had poor response rates to EGFR tyrosine kinase inhibitors (TKIs) including gefitinib, erlotinib, afatinib, and osimertinib, and the heterogeneity of EGFR e20ins further com...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, YanRu, Jian, Hong, Tong, Xiaoling, Wu, Xue, Wang, Fufeng, Shao, Yang W., Zhao, Xinmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400778/
https://www.ncbi.nlm.nih.gov/pubmed/32412152
http://dx.doi.org/10.1002/1878-0261.12710

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400778/
https://www.ncbi.nlm.nih.gov/pubmed/32412152
http://dx.doi.org/10.1002/1878-0261.12710

Ejemplares similares